Olivier RASCOL

PU-PH

Travaille sur

Abstracts rédigés ou co-rédigés

> Substantia Nigra locations of iron-content and free-water abnormalities in Parkinson’s Disease.
Arribarat G, Pasternak O, De Barros A, Galitky M, Rascol O, Péran P.
5th Congress of the European Academy of Neurology, EAN 2019, 29 juin- 2 Juillet 2019 à Oslo, Norvège.
> A whole-brain multimodal discrimination of Parkinsons dDiseas, Multiple System Atrophy and Controls.
F Nemmi, A Pavy-Le Traon, O Phillips, M Galitzky, W Meissner, O Rascol, P Péran .
5th Congress of the European Academy of Neurology, EAN 2019, 29 juin- 2 Juillet 2019 à Oslo, Norvège.
> A whole-brain multimodal discrimination of Parkinsons dDiseas, Multiple System Atrophy and Controls.
F Nemmi, A Pavy-Le Traon, O Phillips, M Galitzky, W Meissner, O Rascol, P Péran
Organization for Human Brain Mapping,OHBM 2019, 9-13 juin 2019 à Rome, Italie.
> Longitudinal changes of R2 star and diffusion parameters in substantia nigra of Parkinson’s disease patients.
G.Arribarat, O. Pasternak, O. Rascol, P. Péran.
8th European Conference onClinical Neuroimaging, 20-21 Mai 2018, Bruxelles, Belgique.

Publications rédigées ou co-rédigées

> 7- Parkinson’s Disease Drug Development Since 1999: A Story of Repurposing and Relative Success.
Boucherie DM, Duarte GS, Machado T, Faustino PR, Sampaio C, Rascol O, Ferreira JJ.
Voir la publication
J Parkinsons Dis. 2021 Jan 11. doi: 10.3233/JPD-202184.
> 2- Personality dimensions of patients can change during the course of parkinson’s disease.
Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Croiset A, Ory-Magne F, Rascol O, Moreau C, Rolland AS, Maltête D, Rouaud T, Meyer M, Drapier S, Giordana B, Anheim M, Hainque E, Jarraya B, Benatru I, Auzou N, Belamri L, Tir M, Marques AR, Thobois S, Eusebio A, Corvol JC, Devos D, Brefel-Courbon C; PREDI-STIM study group.
Voir la publication
PLoS One. 2021 Jan 7;16(1):e0245142. doi: 10.1371/journal.pone.0245142.
> 32- Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinson’s Disease Patients (PSYCHO-STIM).
Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Ory-Magne F, Rascol O, Moreau C, Maltête D, Rouaud T, Meyer M, Houvenaghel JF, Marsé C, Tranchant C, Hainque E, Jarraya B, Ansquer S, Bonnet M, Belamri L, Tir M, Marques AR, Danaila T, Eusebio A, Devos D, Brefel-Courbon C; PREDI-STIM study group.
Voir la publication
J Parkinsons Dis. 2020 May 16. doi: 10.3233/JPD-191903.
> 53- Multiple System Atrophy: Recent Developments and Future Perspectives
Meissner WG, Fernagut PO, Dehay B, Péran P, Traon AP, Foubert-Samier A, Lopez Cuina M, Bezard E, Tison F, Rascol O.
Mov Disord. 2019 Nov 6. doi: 10.1002/mds.27894.
> 67- Multiple System Atrophy: Recent Developments and Future Perspectives.
Meissner WG, Fernagut PO, Dehay B, Péran P, Traon AP, Foubert-Samier A, Lopez Cuina M, Bezard E, Tison F, Rascol O.
Voir la publication
Mov Disord. 2019 Nov;34(11):1629-1642. doi: 10.1002/mds.27894. Epub 2019 Nov 6. Review.
> 25- A totally data-driven whole-brain multimodal pipeline for the discrimination of Parkinson’s disease, multiple system atrophy and healthy control
Nemmi F, Pavy-Le Traon A, Phillips O.R, Galitzky M, Meissner W.G, Rascol O, Péran P
NeuroImage Clinical
> 30- Substantia nigra locations of iron-content, free-water and mean diffusivity abnormalities in moderate stage Parkinson’s disease.
Arribarat G, Pasternak O, De Barros A, Galitzky M, Rascol O, Péran P.
Parkinsonism Relat Disord. 2019 May 22. pii: S1353-8020(19)30254-8. doi: 10.1016/j.parkreldis.2019.05.033.
> 22- How to diagnose parkinsonian central pain?
Marques A, Attal N, Bouhassira D, Moisset X, Cantagrel N, Rascol O, Durif F, Brefel-Courbon C.
Parkinsonism Relat Disord. 2019 May 1. pii: S1353-8020(19)30220-2. doi: 10.1016/j.parkreldis.2019.04.025.
> 63- Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type.
Vergnet S, Hives F, Foubert-Samier A, Payoux P, Fernandez P, Meyer M, Dupouy J, Brefel-Courbon C, Ory-Magne F, Rascol O, Tison F, Pavy-Le Traon A, Meissner WG.
Voir la publication
Parkinsonism Relat Disord. 2019 Jun;63:199-203. doi: 10.1016/j.parkreldis.2019.02.006. Epub 2019 Feb 5.
> 20- Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson’s disease cohort?
Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carrière N, Danaila T, Defebvre L, Defer G, Dellapina E, Doé de Maindreville A, Geny C, Maltête D, Meissner WG, Rascol O, Thobois S, Torny F, Tranchant C, Vidailhet M, Corvol JC, Degos B; NS-Park/F-CRIN Network study group.
Parkinsonism Relat Disord. 2019 Apr 25. pii: S1353-8020(19)30207-X. doi: 10.1016/j.parkreldis.2019.04.012.
> 5- MRI supervised and unsupervised classification of Parkinson’s disease and multiple system atrophy.
Péran P, Barbagallo G, Nemmi F, Sierra M, Galitzky M, Traon AP, Payoux P, Meissner WG, Rascol O.
Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27307.
> 66- Abnormal pain perception in patients with Multiple System Atrophy.
Ory-Magne F, Pellaprat J, Harroch E, Galitzsky M, Rousseau V, Pavy-Le Traon A, Rascol O, Gerdelat A, Brefel-Courbon C.
Parkinsonism Relat Disord. 2017 Dec 8. pii: S1353-8020(17)30827-1. doi: 10.1016/j.parkreldis.2017.12.001.
> 1- Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson’s disease.
Montastruc F, Moulis F, Araujo M, Chebane L, Rascol O, Montastruc JL.
Eur J Clin Pharmacol. 2017 Jan;73(1):99-103. doi: 10.1007/s00228-016-2142-x.
> 20- Unmasking levodopa resistance in Parkinson’s disease.
Nonnekes J, Timmer MH, de Vries NM, Rascol O, Helmich RC, Bloem BR.
Mov Disord. 2016 Nov;31(11):1602-1609. doi: 10.1002/mds.26712.
> 24- The safety and efficacy of safinamide mesylate for the treatment of Parkinson’s disease.
Perez-Lloret S, Rascol O.
Expert Rev Neurother. 2016;16(3):245-58. doi: 10.1586/14737175.2016.1150783. Review.
> 25- A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B.
Mov Disord. 2016 Jul;31(7):1049-54. doi: 10.1002/mds.26569.
> 45- Atropinic (Anticholinergic) Burden in Parkinson’s Disease.
De Germay S, Montastruc JL, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Rascol O, Pariente A, Bégaud B, Montastruc F.
Mov Disord. 2016 May;31(5):632-6. doi: 10.1002/mds.26595.
> 34- Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease.
Barbagallo G, Sierra-Peña M, Nemmi F, Traon AP, Meissner WG, Rascol O, Péran P.
Mov Disord. 2016 Mar;31(3):325-34. doi: 10.1002/mds.26471.
> 26- Espresso Coffee for the Treatment of Somnolence in Parkinson’s Disease: Results of n-of-1 Trials.
Ferreira JJ, Mestre T, Guedes LC, Coelho M, Rosa MM, Santos AT, Barra M, Sampaio C, Rascol O.
Front Neurol. 2016 Mar 8;7:27. doi: 10.3389/fneur.2016.00027.
> Subjective sleep dysfunction and insomnia symptoms in Parkinson’s disease: Insights from a cross-sectional evaluation of the French CoPark cohort.
Ratti PL, Nègre-Pagès L, Pérez-Lloret S, Manni R, Damier P, Tison F, Destée A, Rascol O.
Parkinsonism Relat Disord. 2015 Nov;21(11):1323-9. doi: 10.1016/j.parkreldis.2015.09.025.
> Falls in ambulatory non-demented patients with Parkinson’s disease.
Rascol O, Perez-Lloret S, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Tison F, Negre-Pages L.
J Neural Transm (Vienna). 2015 Oct;122(10):1447-55. doi: 10.1007/s00702-015-1396-2.
> New treatments for levodopa-induced motor complications.
Rascol O, Perez-Lloret S, Ferreira JJ.
Mov Disord. 2015 Sep 15;30(11):1451-60. doi: 10.1002/mds.26362. Review.
> Distinctive features of NREM parasomnia behaviors in parkinson’s disease and multiple system atrophy.
Ratti PL, Sierra-Peña M, Manni R, Simonetta-Moreau M, Bastin J, Mace H, Rascol O, David O.PLoS One.
2015 Mar 10;10(3):e0120973. doi: 10.1371/journal.pone.0120973.
> Parkinson’s disease and local atrophy in subcortical nuclei: insight from shape analysis.
Nemmi F, Sabatini U, Rascol O, Péran P.
Neurobiol Aging. 2015 Jan;36(1):424-33. doi: 10.1016/j.neurobiolaging.2014.07.010.
> Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, Gomez-Mancilla B.
Parkinsonism Relat Disord. 2014 Sep;20(9):947-56. doi:
> Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, Gomez-Mancilla B.
Parkinsonism Relat Disord. 2014 Sep;20(9):947-56. doi: 10.1016/j.parkreldis.2014.05.003. Review.
> Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies.
Fernagut PO, Dehay B, Maillard A, Bezard E, Perez P, Pavy-Le Traon A, Rascol O, Foubert-Samier A, Tison F, Meissner WG.
Neurobiol Dis. 2014 Jul;67:133-9. doi: 10.1016/j.nbd.2014.03.021. Review.
> Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies.
Fernagut PO, Dehay B, Maillard A, Bezard E, Perez P, Pavy-Le Traon A, Rascol O, Foubert-Samier A, Tison F, Meissner WG.
Neurobiol Dis. 2014 Jul;67:133-9. doi: 10.1016/j.nbd.2014.03.021. Review.
> Risk of heart failure following treatment with dopamine agonists in Parkinson’s disease patients.
Perez-Lloret S, Rey MV, Crispo J, Krewski D, Lapeyre-Mestre M, Montastruc JL, Rascol O.
Expert Opin Drug Saf. 2014 Mar;13(3):351-60. doi: 10.1517/14740338.2014.888057. Review.
> Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O; NS-Park CIC Network..
Neurology. 2014 Jan 28;82(4):300-7. doi: 10.1212/WNL.0000000000000050.